vs
Alpha Cognition Inc.（ACOG）与BioNTech SE（BNTX）财务数据对比。点击上方公司名可切换其他公司
BioNTech SE的季度营收约是Alpha Cognition Inc.的543.8倍（$1.5B vs $2.8M）。BioNTech SE净利率更高（-1.9% vs -245.5%，领先243.6%）
BioNTech SE是总部位于德国美因茨的跨国生物技术企业，专注于免疫疗法及疫苗研发工作，核心研究方向覆盖肿瘤、传染性疾病等医疗领域，相关技术处于全球生物医药行业领先水平。
ACOG vs BNTX — 直观对比
营收规模更大
BNTX
是对方的543.8倍
$2.8M
净利率更高
BNTX
高出243.6%
-245.5%
损益表 — Q4 2025 vs Q3 2025
| 指标 | | |
|---|---|---|
| 营收 | $2.8M | $1.5B |
| 净利润 | $-6.9M | $-28.7M |
| 毛利率 | — | — |
| 营业利润率 | -283.7% | -3.1% |
| 净利率 | -245.5% | -1.9% |
| 营收同比 | — | — |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.10 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACOGBNTX
| Q4 25 | $2.8M | — | ||
| Q3 25 | $2.8M | $1.5B | ||
| Q2 25 | $1.7M | $260.8M | ||
| Q1 25 | $2.9M | $182.8M | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $128.7M | ||
| Q1 24 | — | $187.6M |
净利润ACOGBNTX
| Q4 25 | $-6.9M | — | ||
| Q3 25 | $-1.3M | $-28.7M | ||
| Q2 25 | $-10.5M | $-386.6M | ||
| Q1 25 | $-2.0M | $-415.8M | ||
| Q3 24 | — | $198.1M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
毛利率ACOGBNTX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 96.7% | — | ||
| Q1 25 | 99.6% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率ACOGBNTX
| Q4 25 | -283.7% | — | ||
| Q3 25 | -187.0% | -3.1% | ||
| Q2 25 | -346.1% | -192.1% | ||
| Q1 25 | -125.9% | -292.2% | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | — | -750.7% | ||
| Q1 24 | — | -270.4% |
净利率ACOGBNTX
| Q4 25 | -245.5% | — | ||
| Q3 25 | -46.4% | -1.9% | ||
| Q2 25 | -632.7% | -148.2% | ||
| Q1 25 | -68.5% | -227.5% | ||
| Q3 24 | — | 15.9% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
每股收益（稀释后）ACOGBNTX
| Q4 25 | $-0.10 | — | ||
| Q3 25 | $-0.30 | — | ||
| Q2 25 | $-0.65 | — | ||
| Q1 25 | $-0.13 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $66.0M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $62.5M | — |
| 总资产 | $79.7M | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACOGBNTX
| Q4 25 | $66.0M | — | ||
| Q3 25 | $35.4M | — | ||
| Q2 25 | $39.4M | — | ||
| Q1 25 | $45.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ACOGBNTX
| Q4 25 | $62.5M | — | ||
| Q3 25 | $33.9M | — | ||
| Q2 25 | $31.9M | — | ||
| Q1 25 | $40.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
总资产ACOGBNTX
| Q4 25 | $79.7M | — | ||
| Q3 25 | $46.3M | — | ||
| Q2 25 | $45.1M | — | ||
| Q1 25 | $48.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.9M | — |
| 自由现金流经营现金流 - 资本支出 | $-7.1M | — |
| 自由现金流率自由现金流/营收 | -252.6% | — |
| 资本支出强度资本支出/营收 | 5.3% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-20.7M | — |
8季度趋势，按日历期对齐
经营现金流ACOGBNTX
| Q4 25 | $-6.9M | — | ||
| Q3 25 | $-5.3M | — | ||
| Q2 25 | $-6.1M | — | ||
| Q1 25 | $-2.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流ACOGBNTX
| Q4 25 | $-7.1M | — | ||
| Q3 25 | $-5.4M | — | ||
| Q2 25 | $-6.1M | — | ||
| Q1 25 | $-2.1M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率ACOGBNTX
| Q4 25 | -252.6% | — | ||
| Q3 25 | -188.8% | — | ||
| Q2 25 | -370.9% | — | ||
| Q1 25 | -72.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度ACOGBNTX
| Q4 25 | 5.3% | — | ||
| Q3 25 | 2.6% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 2.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
